CO5050328A1 - Sistema solvente para la mejor penetracion de compuestos farmaceuticos - Google Patents

Sistema solvente para la mejor penetracion de compuestos farmaceuticos

Info

Publication number
CO5050328A1
CO5050328A1 CO98017937A CO98017937A CO5050328A1 CO 5050328 A1 CO5050328 A1 CO 5050328A1 CO 98017937 A CO98017937 A CO 98017937A CO 98017937 A CO98017937 A CO 98017937A CO 5050328 A1 CO5050328 A1 CO 5050328A1
Authority
CO
Colombia
Prior art keywords
solvent system
pharmaceutical compounds
best penetration
penetration
composition
Prior art date
Application number
CO98017937A
Other languages
English (en)
Inventor
S Rao Chakradhara
Liu Jue-Chen
Jonas C T Wang
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of CO5050328A1 publication Critical patent/CO5050328A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UNA COMPOSICION QUE CONSISTE DE UN COM PUESTO O DROGA FARMACEUTICAMENTE TOPICAMENTE ACTI- VO Y UN SISTEMA SOLVENTE BUFFER CAPAZ DE MEJORAR LA PENETRACION DE DICHA DROGA. EL SISTEMA SOLVEN- TE BUFFER PERMITE A UNA CANTIDAD REDUCIDA DEL COM- PUESTO FARMACEUTICO DE LA COMPOSICION NO ALTERAR SIGNIFICATIVAMENTE LA EFICACIA DE DICHO COMPUESTO.
CO98017937A 1997-03-31 1998-03-31 Sistema solvente para la mejor penetracion de compuestos farmaceuticos CO5050328A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82909197A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
CO5050328A1 true CO5050328A1 (es) 2001-06-27

Family

ID=25253504

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98017937A CO5050328A1 (es) 1997-03-31 1998-03-31 Sistema solvente para la mejor penetracion de compuestos farmaceuticos

Country Status (14)

Country Link
EP (1) EP0971746A1 (es)
JP (1) JP2001518879A (es)
KR (1) KR19980081207A (es)
CN (1) CN1252003A (es)
AR (1) AR012217A1 (es)
AU (1) AU6677698A (es)
BR (1) BR9811458A (es)
CA (1) CA2285368A1 (es)
CO (1) CO5050328A1 (es)
HU (1) HUP0001739A3 (es)
IL (1) IL132096A0 (es)
PL (1) PL335934A1 (es)
WO (1) WO1998043673A1 (es)
ZA (1) ZA982662B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
AU5146600A (en) * 1999-05-27 2000-12-18 Procter & Gamble Company, The Topical compositions providing improved treatment of skin or scalp fungal infections
GB0103046D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP4784051B2 (ja) * 2003-07-03 2011-09-28 大正製薬株式会社 容器への吸着を防止した外用抗真菌組成物
JP5435836B2 (ja) * 2003-07-03 2014-03-05 大正製薬株式会社 外用抗真菌剤組成物
DE102005059742A1 (de) 2005-12-13 2007-06-14 Beiersdorf Ag Transparentes Sonnenschutzmittel
US20080032994A1 (en) 2006-08-03 2008-02-07 Marcel Borgers Modified azole compounds as antifungal and antibacterial agents
ATE481964T1 (de) * 2007-07-25 2010-10-15 Ixodes Gmbh Topische antibiotische zusammensetzung zur prävention von lyme-borreliose
ES2588188T3 (es) 2007-08-27 2016-10-31 Nihon Nohyaku Co., Ltd. Agente para la dermatitis fúngica
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US9839611B2 (en) * 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
MY179756A (en) 2013-10-03 2020-11-12 Dow Pharmaceutical Sciences Stabilized efinaconazole formulations
JP6611014B2 (ja) 2013-11-22 2019-11-27 ボシュ ヘルス アイルランド リミテッド 抗感染方法、抗感染組成物、および抗感染装置
CN115745757B (zh) * 2022-11-07 2024-04-26 中国人民解放军军事科学院军事医学研究院 一种液态多甘醇柱芳烃衍生物的合成及对经皮药效分子缓释的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331137C (en) * 1988-02-29 1994-08-02 Pfizer, Inc. Transdermal flux enhancing compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CN1106259A (zh) * 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂

Also Published As

Publication number Publication date
WO1998043673A1 (en) 1998-10-08
IL132096A0 (en) 2001-03-19
BR9811458A (pt) 2000-09-19
HUP0001739A3 (en) 2001-04-28
ZA982662B (en) 1999-09-30
KR19980081207A (ko) 1998-11-25
HUP0001739A2 (hu) 2000-12-28
JP2001518879A (ja) 2001-10-16
CN1252003A (zh) 2000-05-03
AR012217A1 (es) 2000-09-27
PL335934A1 (en) 2000-05-22
EP0971746A1 (en) 2000-01-19
CA2285368A1 (en) 1998-10-08
AU6677698A (en) 1998-10-22

Similar Documents

Publication Publication Date Title
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
BR0015605A (pt) Composição e uso
CR7173A (es) Composicion permeable por la piel de un inhibidor selectivo de ciclooxigenasa-2
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
AR021912A1 (es) Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
PA8515601A1 (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene